Abstract

Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding how to increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.

Keywords

ImmunotherapyCancer immunotherapyMedicineCancerAdverse effectDrug deliveryImmune systemClinical trialDrugImmunologyPharmacologyInternal medicineNanotechnology

MeSH Terms

AnimalsDrug Delivery SystemsHumansImmunotherapyNanoparticlesNeoplasmsT-Lymphocytes

Affiliated Institutions

Related Publications

Publication Info

Year
2019
Type
review
Volume
18
Issue
3
Pages
175-196
Citations
2469
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2469
OpenAlex
33
Influential

Cite This

Rachel Riley, Carl H. June, Róbert Langer et al. (2019). Delivery technologies for cancer immunotherapy. Nature Reviews Drug Discovery , 18 (3) , 175-196. https://doi.org/10.1038/s41573-018-0006-z

Identifiers

DOI
10.1038/s41573-018-0006-z
PMID
30622344
PMCID
PMC6410566

Data Quality

Data completeness: 86%